Vall d'Hebron is one of the centers that coordinate this network, which so far has enabled the detection of high-risk genetic alterations and the provision of personalized treatments that have already achieved remission in cases with very few therapeutic alternatives.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.

A new publication describes the creation of this initiative, which has facilitated access to genomic studies for more than 900 pediatric patients with cancer from across Spain.

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The charitable initiative, launched by the Terrassa Municipal Police, funds the doctoral thesis of predoctoral researcher María Gallego.

The integration of Patient-Reported Outcome Measures (PROMs) will make it possible to incorporate patients' experiences and quality of life into research on sickle cell disease and other rare anaemias.

The Scientific Coordinator of ERN-EuroBloodNet will lead for one year the group that defines the common strategy of the European Reference Networks to improve care for rare and complex diseases.

Vall d’Hebron participates as a reference centre in Spain for early-phase clinical trials and coordinates the national ReALLNet network, promoting research into relapsed acute lymphoblastic leukemia.

The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.

The European initiative Hope4Kids will strengthen and harmonise paediatric palliative care across Europe, with the aim of ensuring comprehensive, high-quality care for all children living with life-threatening or life-limiting conditions.

The initiative will enable young people aged 12 to 18 to collaborate with campus researchers in the design, development and communication of scientific projects, placing patients and families at the centre of the research process.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.

The charitable initiative created in honor of Pol is supporting a research project aimed at identifying therapeutic targets to treat a rare type of leukemia.

The initiative aims to transform and improve how clinical trials are conducted in the field of rare diseases.

The charitable initiative will allocate all funds to research on pediatric nervous system tumors carried out at the Vall d’Hebron Research Institute

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The Iris Association has made a €14,499 donation to the Childhood Cancer and Hematological Diseases Group at the Vall d’Hebron Research Institute (VHIR).

The funds raised will contribute to ensuring the continuity of the pediatric brain tumor research line developed by the Vall d’Hebron research teams.